Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.

Vardon A, Dandapani M, Cheng D, Cheng P, De Santo C, Mussai F.

Oncotarget. 2017 Jun 29;8(38):63506-63517. doi: 10.18632/oncotarget.18843. eCollection 2017 Sep 8.

2.

Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes.

Bobak YP, Vynnytska BO, Kurlishchuk YV, Sibirny AA, Stasyk OV.

Cell Biol Int. 2010 Nov;34(11):1085-9. doi: 10.1042/CBI20100451.

PMID:
20653567
3.

The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.

De Santo C, Booth S, Vardon A, Cousins A, Tubb V, Perry T, Noyvert B, Beggs A, Ng M, Halsey C, Kearns P, Cheng P, Mussai F.

Int J Cancer. 2018 Apr 1;142(7):1490-1502. doi: 10.1002/ijc.31170. Epub 2017 Dec 26.

4.
5.

Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects.

Nagasaka H, Tsukahara H, Yorifuji T, Miida T, Murayama K, Tsuruoka T, Takatani T, Kanazawa M, Kobayashi K, Okano Y, Takayanagi M.

Metabolism. 2009 Mar;58(3):278-82. doi: 10.1016/j.metabol.2008.09.025.

PMID:
19217439
6.

Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression.

Werner A, Koschke M, Leuchtner N, Luckner-Minden C, Habermeier A, Rupp J, Heinrich C, Conradi R, Closs EI, Munder M.

Front Immunol. 2017 Jul 24;8:864. doi: 10.3389/fimmu.2017.00864. eCollection 2017.

7.

Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F.

J Hematol Oncol. 2018 May 18;11(1):68. doi: 10.1186/s13045-018-0612-6.

8.

Argininosuccinate synthetase and argininosuccinate lyase: two ornithine cycle enzymes from Agaricus bisporus.

Wagemaker MJ, Eastwood DC, van der Drift C, Jetten MS, Burton K, Van Griensven LJ, Op den Camp HJ.

Mycol Res. 2007 Apr;111(Pt 4):493-502. Epub 2007 Feb 8.

PMID:
17512708
9.

Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain.

Swamy M, Zakaria AZ, Govindasamy C, Sirajudeen KN, Nadiger HA.

Neurosci Res. 2005 Oct;53(2):116-22.

PMID:
16009439
10.

Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Fultang L, Vardon A, De Santo C, Mussai F.

Int J Cancer. 2016 Aug 1;139(3):501-9. doi: 10.1002/ijc.30051. Epub 2016 Apr 15. Review.

11.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C.

Blood. 2015 Apr 9;125(15):2386-96. doi: 10.1182/blood-2014-09-600643. Epub 2015 Feb 20.

12.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N.

Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.

13.
14.

Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma.

Lam SK, Yan S, Xu S, U KP, Cheng PN, Ho JC.

Oncogenesis. 2019 Feb 26;8(3):18. doi: 10.1038/s41389-019-0128-0.

15.

The human neonatal small intestine has the potential for arginine synthesis; developmental changes in the expression of arginine-synthesizing and -catabolizing enzymes.

Köhler ES, Sankaranarayanan S, van Ginneken CJ, van Dijk P, Vermeulen JL, Ruijter JM, Lamers WH, Bruder E.

BMC Dev Biol. 2008 Nov 10;8:107. doi: 10.1186/1471-213X-8-107.

16.

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.

Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA.

Cancer. 2004 Feb 15;100(4):826-33.

17.

Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Phillips MM, Sheaff MT, Szlosarek PW.

Cancer Res Treat. 2013 Dec;45(4):251-62. doi: 10.4143/crt.2013.45.4.251. Epub 2013 Dec 31. Review.

18.

The subcellular compartmentalization of arginine metabolizing enzymes and their role in endothelial dysfunction.

Chen F, Lucas R, Fulton D.

Front Immunol. 2013 Jul 9;4:184. doi: 10.3389/fimmu.2013.00184. eCollection 2013.

19.

Expression and localization of enzymes of arginine metabolism in the rat eye.

Koshiyama Y, Gotoh T, Miyanaka K, Kobayashi T, Negi A, Mori M.

Curr Eye Res. 2000 Apr;20(4):313-21.

PMID:
10806445
20.

Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S.

J Pathol Clin Res. 2014 Nov 5;1(1):41-53. doi: 10.1002/cjp2.4. eCollection 2015 Jan.

Supplemental Content

Support Center